Kendalle Burlin O'Connell, Esq.’s Post

$AGLE - Is Aeglea Bio a good shorter-term buy? Next financial report is on 9th of May 2024.: About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aeglea Bio Therapeutics recorded a loss per share of 74.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 8th of September 2023. #stocks #stocktwits #thematic_portfolio

Peek into the future! Piper Sandler unveils top biotech stock picks for 2024. The next big players in the biotech industry! 🧬💡 Piper Sandler Reveals 2024’S Top Biotech Stock Selections Read More: https://shorturl.at/pFPQZ #BiotechStocks #InvestingInnovation #PiperSandler #FutureTrends #BiotechInvesting #MarketInsights

𝗔𝗿𝗿𝗶𝗩𝗲𝗻𝘁 𝗼𝘂𝘁𝗹𝗶𝗻𝗲𝘀 𝗽𝗹𝗮𝗻𝘀 𝗳𝗼𝗿 $𝟭𝟯𝟱𝗠 𝗜𝗣𝗢 𝗶𝗻 𝘀𝗲𝗰𝗼𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗹𝗶𝘀𝘁𝗶𝗻𝗴 𝗼𝗳 𝟮𝟬𝟮𝟰 ArriVent Biopharma, a Pennsylvania drugmaker developing a China-approved cancer treatment for the US and other geographies, plans to raise net proceeds of about $135 million in its Nasdaq listing. It would be the second biotech IPO of the year after CG Oncology last week outlined its pitch for a $181 million Wall Street debut. ArriVent plans on selling 8.33 million shares in its IPO and expects to price at $17 to $19 per share $AVBP, per a Monday morning SEC filing. Biotechs tend to go public within a week of penciling in their price range. Zhengbin (Bing) Yao, CEO pictured. More below: https://lnkd.in/dp6BXWbw

Last week the Nordic healthcare stocks delivered a strong performance. The KPHC index rose 2.4% and the Danish stocks rose 7.4%. Gubra’s CEO sold shares for around DKK 30 million, Acarix carried out a directed issue of SEK 21 million, and SynAct initiated the filing process for the phase IIb study with Resomelagon. Finally, CS Medica’s stock is now traded on XETRA, in a move for increased liquidity. 6 Danish healthcare stocks delivered a +20% return. Read more: https://lnkd.in/dWH72rBj Acarix Ascendis Pharma Biosergen CS MEDICA Curasight Evaxion Biotech A/S ExpreS2ion Biotechnologies FluoGuide A/S Genmab Gubra IO Biotech PILA PHARMA Saniona SynAct Pharma ViroGates Zealand Pharma Y-mAbs Therapeutics, Inc. 2cureX - Individualizing Cancer Treatment

$AGLE - Ready to toss Aeglea Bio? Next financial report is on 9th of May 2024.: About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aeglea Bio Therapeutics recorded a loss per share of 74.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 8th of September 2023. https://lnkd.in/gPh3T6R9 #stocks #stocktwits #thematic_portfolio

Aprea Therapeutics ( $APRE ) social hype OVER HYPED. Current probability of distress is under 8%: Net Loss for the year was (14.29 M) with profit before overhead, payroll, taxes, and interest of 0. Aprea Therapeutics defends 59.44 z score. Aprea Therapeutics is selling at 6.69. That is 10.21 percent increase. Started trading at 6.07. https://lnkd.in/gX6dzdse #trading #ideas #stocks

Did you know autoimmune diseases impact 10% of the global population? 🔍 Zoom in on Abivax, a clinical-stage biotechnology company revolutionizing treatments for conditions like IBD with their lead drug, obefazimod. 💡 Abivax was recently listed on Nasdaq, raising USD 236 million in the largest IPO by a French biotech. This marks Bryan Garnier’s 6th financing transaction with Abivax since 2020, and adds to our track record of over 20 IPOs and follow-ons led for European growth companies on the US NASDAQ. 🌈 Abivax is bringing new hope to autoimmune disease patients. Join us in celebrating their groundbreaking strides! 🌐 Marc de Garidel, Didier Blondel   Olivier Garnier, Pierre Kiecolt-Wahl, Vincent Meunier, Theodore de Charsonville, Hugo Fischer  #BiotechInnovation #Abivax #Crohn #Inflammation #AutoimmuneDiseases #IPO #NASDAQ

In this week’s highlights from companies listed on the Aquis Stock Exchange: 💊 Psych Capital Plc acquired the life science company Shortwave Pharma Inc, which is developing breakthrough therapies to address unmet medical needs in mental health. 🌿 Ananda Developments Plc’s wholly owned subsidiary MRX Medical Limited (MRX) filed a fifth patent application for a new cannabinoid formulation known as MRX2T. It also announced that CEO Melissa Sturgess will provide a live company update via Investor Meet Company on Tuesday 14th November at 9:00am GMT. Investors can register for free here: https://shorturl.at/diEX7 📈 FIELD SYSTEMS DESIGNS HOLDINGS PLC announced results for the year ended 31 May 2023, with an improved 70% year-to-year turnover of £13.8 million, making the company profitable. 🏚 Black Sea Property PLC provided an update on the acquisition of Grand Hotel Varna. 💲 Vinanz Limited raised £350,000 at 3.0 pence per share to be used primarily to acquire 250 additional bitcoin miners which will approximately triple its Bitcoin mining fleet in North America. 🏨 Daniel Thwaites announced interim results for the six months ended 30 September 2023, showing a 4% increase in turnover compared to last year.  Read the full announcements here: https://lnkd.in/eatn9iGh

Social Pharma Patient-Centric Marketing socialpharma.net >>> Gene&Cell Therapy >> Four buyouts (and one rumor that didn’t materialize); Isomorphic Labs' first pharma deals; A CAR-T IPO; #JPM24 highlights; and more #lucidquest #genetherapy #celltherapy

Thoughts on this? >> Biotech industry flirts with XBI milestone as it surpasses $100 >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #productmarketing